Climb Bio Inc (CLYM) - Total Assets
Based on the latest financial reports, Climb Bio Inc (CLYM) holds total assets worth $152.37 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Climb Bio Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
Climb Bio Inc - Total Assets Trend (2019–2025)
This chart illustrates how Climb Bio Inc's total assets have evolved over time, based on quarterly financial data. See Climb Bio Inc net assets for net asset value and shareholders' equity analysis.
Climb Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Climb Bio Inc's total assets of $152.37 Million consist of 63.1% current assets and 36.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Climb Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CLYM stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Climb Bio Inc's current assets represent 63.1% of total assets in 2025, a decrease from 99.5% in 2019.
- Cash Position: Cash and equivalents constituted 21.3% of total assets in 2025, down from 99.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Climb Bio Inc Competitors by Total Assets
Key competitors of Climb Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Climb Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 27.86 | 14.25 | 18.34 |
| Quick Ratio | 27.86 | 14.25 | 18.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $109.33 Million | $93.24 Million | $99.09 Million |
Climb Bio Inc - Advanced Valuation Insights
This section examines the relationship between Climb Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.22 |
| Latest Market Cap to Assets Ratio | 3.72 |
| Asset Growth Rate (YoY) | -22.8% |
| Total Assets | $167.74 Million |
| Market Capitalization | $624.74 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Climb Bio Inc's assets at a significant premium (3.72x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Climb Bio Inc's assets decreased by 22.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Climb Bio Inc (2019–2025)
The table below shows the annual total assets of Climb Bio Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $167.74 Million | -22.77% |
| 2024-12-31 | $217.19 Million | +96.60% |
| 2023-12-31 | $110.47 Million | -18.17% |
| 2022-12-31 | $134.99 Million | -22.08% |
| 2021-12-31 | $173.24 Million | +603.35% |
| 2020-12-31 | $24.63 Million | +15.13% |
| 2019-12-31 | $21.39 Million | -- |
About Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary me… Read more